Will AbbVie’s $10.9 Billion Acquisition Shape Its Dividend?
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
New to investing? Check out these zero fee investment apps designed specifically for new investors to start building wealth.
28,005 articlesAbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
A major stake sale can ripple through markets and portfolios. This article breaks down what arena capital sells milli...
Signet Jewelers stock just moved higher as the company rolls out a growth strategy focused on core brands and smarter...
A major fund recently trimmed its stake in Viridian Therapeutics, signaling potential rotation rather than a verdict ...
Microsoft stock sinking today has investors looking past a single bad headline. This deep-dive explains the drivers b...
NVIDIA’s latest announcements are stirring chatter about AI-driven growth and new catalysts. Here’s what investors sh...
When a company’s CFO sells a sizable block of stock, investors sit up and take notice. This article breaks down what ...
Rivian faces a challenging journey into 2026, with big questions about profitability, demand, and policy shifts. This...
Rigetti Computing lives at the edge of technology and finance. This article breaks down the revenue puzzle, the risks...
This article dives into Black Hills’ Q1 2026 earnings transcript, translating the numbers into actionable insights. L...
A new AI chip contender is entering the arena. This guide examines whether could cerebras next nvidia? is a realistic...
A bold investment thesis hinges on the AI inference niche. After June 3, the market could reward execution as much as...